Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of “Buy” from Analysts

Alumis Inc. (NASDAQ:ALMS) has been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $27.50.

A number of research analysts have recently commented on ALMS shares. Leerink Partnrs raised Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Monday, August 19th. HC Wainwright began coverage on shares of Alumis in a research note on Thursday, October 17th. They issued a “buy” rating and a $30.00 price objective for the company. Guggenheim began coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Alumis in a report on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price on the stock.

Institutional Trading of Alumis

A number of hedge funds have recently bought and sold shares of the stock. Towerview LLC raised its holdings in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after acquiring an additional 70,000 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Alumis during the 2nd quarter worth approximately $332,000. Millennium Management LLC bought a new stake in shares of Alumis during the second quarter valued at approximately $3,376,000. Yu Fan acquired a new position in shares of Alumis in the second quarter valued at $10,502,000. Finally, Ally Bridge Group NY LLC bought a new position in Alumis in the second quarter worth $8,229,000.

Alumis Trading Up 2.7 %

Shares of ALMS opened at $12.02 on Monday. The business’s fifty day simple moving average is $11.39. Alumis has a 12 month low of $9.54 and a 12 month high of $13.53.

Alumis (NASDAQ:ALMS) last posted its earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing the consensus estimate of ($1.57) by ($21.53). Equities research analysts forecast that Alumis will post -8 earnings per share for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.